Drugs / Sabin inactivated poliovirus vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02985320 | Oct 2016 → Jun 2017 | poliomyelitis | Sinovac Biotech Co., Ltd | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sabin inactivated poliovirus vaccine | “Sabin inactivated poliovirus vaccine (sIPV) should be developed to meet the requirements for biosafety and affordable strategy in the developing countries.” PMID 30249424 ↗ Sep 2018 |
| Known as | sIPV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02985320 ↗ |
| Modality | Vaccine | “Sabin inactivated poliovirus vaccine (sIPV)” NCT02985320 ↗ |